GlassScriptPhysician profile
Anthony Angeloni
NPI 1538814231
$2,623.07
in general payments reported to CMS, 2019-2025
21 companies · $738 in 2025
The $738 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $593 · 2023: $732 · 2024: $561 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028 · Education: $2.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.19 |
| Education | $2.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $781.79 | 2022-2025 | Apretude, Dovato |
| Bausch Health US, LLC | $409.21 | 2022-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $279.43 | 2022-2025 | Trintellix |
| Endo Pharmaceuticals INC. | $243.95 | 2022-2024 | Aveed, Xiaflex, Edex |
| Endo USA, INC. | $160.73 | 2024-2025 | Xiaflex, Aveed |
| Abbvie INC. | $130.23 | 2022-2024 | |
| Tolmar, INC. | $110.80 | 2023-2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $108.84 | 2023-2024 | Quviviq |
| Antares Pharma, INC. | $74.96 | 2023 | Tlando, Xyosted, Nocdurna |
| Lilly USA, LLC | $46.87 | 2025 | Zepbound, Mounjaro |
| Boston Scientific Corporation | $43.58 | 2022-2025 | Ams 700 |
| Acerus Pharmaceuticals Corporation | $37.49 | 2022 | |
| Verity Pharmaceuticals INC. | $35.71 | 2025 | Trelstar |
| Axsome Therapeutics, INC. | $24.07 | 2025 | Auvelity |
| Neos Therapeutics, LP | $22.92 | 2024 | Adzenys Xr-Odt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22.78 | 2022 | |
| Owp Pharmaceuticals, INC. | $21.59 | 2023 | Lamotrigine, Subvenite |
| Halozyme INC | $18.79 | 2023 | |
| Millicent US INC | $18.22 | 2023 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $15.63 | 2022 | |
| Amgen INC. | $15.48 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Angeloni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.